Kymera Therapeutics, Inc.

NASDAQ (USD): Kymera Therapeutics, Inc. (KYMR)

Last Price

37.32

Today's Change

-1.72 (4.40%)

Day's Change

37.18 - 39.40

Trading Volume

286,351

Overview

Market Cap

2 Billion

Shares Outstanding

64 Million

Avg Volume

480,158

Avg Price (50 Days)

42.10

Avg Price (200 Days)

41.67

PE Ratio

-15.95

EPS

-2.34

Earnings Announcement

20-Feb-2025

Previous Close

39.04

Open

38.90

Day's Range

37.1875 - 39.4

Year Range

29.24 - 53.27

Trading Volume

300,739

Price Change Highlight

1 Day Change

-4.41%

5 Day Change

-8.35%

1 Month Change

-8.80%

3 Month Change

-25.15%

6 Month Change

-7.42%

Ytd Change

-8.73%

1 Year Change

10.45%

3 Year Change

-9.11%

5 Year Change

12.21%

10 Year Change

12.21%

Max Change

12.21%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment